Paclitaxel oral - Athenex

Drug Profile

Paclitaxel oral - Athenex

Alternative Names: Oral paclitaxel - Hanmi Pharmaceutical; Oraxol; Paclitaxel/HM 30181A

Latest Information Update: 26 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hanmi Pharmaceutical
  • Developer Athenex; Hanmi Pharmaceutical; PharmaEssentia Corporation; Zenith Technology Corporation
  • Class Antineoplastics; Diterpenes; Paclitaxels; Skin disorder therapies; Small molecules; Taxanes
  • Mechanism of Action Angiogenesis inhibitors; Mitosis inhibitors; P-glycoprotein inhibitors; Platelet-derived growth factor inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemangiosarcoma
  • New Molecular Entity No

Highest Development Phases

  • Phase III Breast cancer
  • Phase II Cancer; Gastric cancer
  • Phase I Oesophageal cancer; Solid tumours

Most Recent Events

  • 22 Oct 2018 Efficacy and adverse events data from a phase I trial in Breast cancer presented at the European Society for Medical Oncology (ESMO-2018)
  • 12 Sep 2018 Athenex and Hanmi Pharmaceutical revise the collaboration agreement to grant Athenex the rights to develop and commercialise Orascovery™-based products in the Middle East, North Africa and South Africa
  • 17 Jul 2018 Athenex plans a phase I trial for Solid tumours (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in USA (PO), (NCT03588039)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top